Powderject stock sinks further on delays to launch of anaesthetic
Wednesday 08 December 1999
The lack of an expected announcement on a deal with SmithKline Beecham, the major pharmaceutical company, compounded a 15 per cent fall in the company's shares.
Powderject said the launch of Lidocaine, an anaesthetic which does not require a needle, could be set back by at least a year because it would now be aimed at children as well as adults. That would mean conducting further trials of the treatment on children, which are more complicated than those on adults.
Paul Drayson, chief executive of Powderject, said: "This was a difficult decision for Powderject to settle the way forward for the Lidocaine project. It would have been easier to stick with the adults-only strategy, but this is the best way to maximise the product in the long term."
He declined to indicate the size of the market for the expanded project but said the move would broadly double Lidocaine's sales.
The group was in advanced discussions with a marketing partner for Lidocaine, he added. However, he would not indicate a new launch date for Lidocaine, which had been expected to hit the market next year.
Dr Drayson also said Powderject's late-stage development of its patented powder-injection technology was taking longer than the company had expected at the time of its flotation in 1997.
Meanwhile, Powderject said its long-term future lay specifically in vaccine delivery. The group would be seeking to acquire both vaccines and vaccine companies in pursuit of its ambitions.
Speculation over a deal with SmithKline Beecham to market a Powderject vaccine for flu sent the shares to an all-time high of 1,005p last month.
Powderject also said a partnership with Boehringer Mannheim on a kidney disease treatment had been terminated.
The news sent the shares 152.5p lower to 830p, wiping pounds 110m from the value of company, now capitalised at pounds 620m. Dr Drayson and his family own a 17 per cent stake.
The company also unveiled positive data on phase two trials of Alprostadil, a treatment for impotent men who can't take oral treatments such as Viagra.
- 1 Michael Brown shooting: Amnesty International sends team within US for first time as National Guard deployed
- 2 James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
- 3 Reading Festival 2014: Tesco branch replaces salad and potatoes for Jagermesiter and vodka
- 4 Here’s the damning letter Robin Williams wrote to his Mrs Doubtfire co-star's principal after they expelled her
- 5 Ferguson protests: 90-year-old Holocaust survivor Hedy Epstein ‘arrested’ by police during St Louis demonstrations
Michael Brown shooting: Amnesty International sends team within US for first time as National Guard deployed
Michael Brown shooting: Ferguson police shoot and kill second young black man
James Foley 'beheaded': Isis video shows militant with British accent 'execute US journalist' – and warns Obama of more to come
Iraq crisis: Islamic State's message to America - 'We will drown you all in blood'
Ferguson: In the heartlands of America, a descent into madness
Isis threat: Cameron wants an alliance with Iran
Crisis? What crisis? A visiting US doctor gives the NHS a rave review
Scottish independence: English people overwhelmingly want Scotland to stay in the UK
Ukip MEP calls for reintroduction of death penalty on fiftieth anniversary of last deaths
Russell Brand calls for Israel boycott: Comedian urges big businesses that 'facilitate the oppression of people in Gaza' to pull funding
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
iJobs Money & Business
£475 - £550 per day + competitive: Orgtel: Senior Technical Accountant-Insuran...
£200 - £290 per annum + competitive: Orgtel: Sales Performance Manager, Key Ba...
£25000 - £30000 per annum + bonus+benefits+package: Harrington Starr: Junior D...
£600 - £800 per day: Harrington Starr: Java/Calypso Developer Java, Calypso, ...